HIMS & HERS HEALTH, INC.
At today's price, HIMS & HERS HEALTH, INC. (HIMS) is priced for today's economics sustained for ~34.9 years. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high. Built from SEC EDGAR filings.
• Hims & Hers is a direct-to-consumer telehealth platform with nearly 2.6 million subscribers, and it became Novo Nordisk's official distribution partner for branded Wegovy and Ozempic after the FDA restricted compounded weight-loss drugs. [Source: HIMS Q1 2026 results, May 2026] • The defining risk is the price: at a triple-digit multiple of a barely-positive operating base, the stock embeds decades of high growth that only about one in seven comparable fast-growers has sustained. • Watch reven
Is HIMS overvalued? See what's priced in →
419 institutional managers reported holding HIMS in 13F filings for the quarter ended 2026-03-31. Together they hold about 63% of the company; the top 10 hold 40%. 75 opened new positions that quarter. Held by BlackRock, Vanguard Group, Morgan Stanley, among others. On the short side, 65.5M shares were sold short as of the 2026-06-15 count, about 29% of shares outstanding (3.5 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
HIMS's share count grew 19% over the past five years even with $175.00M spent on repurchases. It pays no dividend. Cash returned over the past three years: $175.00M in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at HIMS over the trailing three years: 2024: 3 buys totaling $2.08M; 2026: 1 buy totaling $1.17M. 15 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
HIMS's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-08 | -8.7% | -14.7% |
| 2023-11-07 | +7.6% | +22.5% |
| 2024-02-27 | +41.1% | -6.7% |
| 2024-05-07 | +9.7% | +67.5% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
HIMS's latest 8-K filings: 2026-07-01 (items 1.01, 2.03, 9.01); 2026-06-15 (items 5.07); 2026-06-02 (items 1.01, 2.03, 8.01, 9.01); 2026-05-21 (items 1.01, 2.03, 3.02, 9.01); 2026-05-19 (items 8.01, 9.01).
Item codes are the SEC's own classification of what each report discloses. Nothing here is investment advice.
Last analyzed: July 3, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.